Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of U-500R Insulin via Syringe vs CSII and TID vs BID Dosing in T2DM
NCT02588950Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2016
- Primary completion
- May 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of human insulin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Time to Maximum Drug Concentration, Area Under the Concentration Versus Time Curve From Zero to 24 Hours Postdose and 2 more. Started Jan 2016; status: terminated.
02
Drugs
human insulin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02588950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02588950.